Article
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
The Journal of pathology - 1 Mar 2004
Sieben Nathalie L G, Macropoulos Patricia, Roemen Guido M J M, Kolkman-Uljee Sandra M, Jan Fleuren Gert, Houmadi Rifat, Diss Tim, Warren Bretta, Al Adnani Mudher, De Goeij Anton P M, Krausz Thomas, Flanagan Adrienne M
Abstract excerpt
Genes of the RAF family, which mediate cellular responses to growth signals, encode kinases that are regulated by RAS and participate in the RAS/RAF/MEK/ERK/MAP-kinase pathway. Activating mutations in BRAF have recently been identified in melanomas, colorectal cancers, and thyroid and ovarian tumours. In the present study, an extensive characterization of BRAF and KRAS mutations has been performed in 264...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.